2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Hyperaldosteronism
1
Herpes Simplex
1
Hemophilia A
1
Hemangioma, Capillary
1
Heart Failure
1
Heart Arrest
1
Interventions
Cyclophosphamide
2067
Radiotherapy
1990
Cisplatin
1856
Carboplatin
1560
Gemcitabine
1454
Paclitaxel
1320
Bevacizumab
1320
pembrolizumab
1237
Docetaxel
1227
Oxaliplatin
1184
Capecitabine
1176
Fluorouracil
1083
Dexamethasone
979
Magnetic Resonance Spectroscopy
971
Nivolumab
936
Rituximab
929
Drug Therapy
915
Surveys and Questionnaires
898
Doxorubicin
845
Etoposide
843
Radiosurgery
816
Blood Specimen Collection
816
Irinotecan
784
Cytarabine
743
fludarabine
726
Leucovorin
684
Surgical Procedures, Operative
639
Lenalidomide
618
Biopsy
594
fludarabine phosphate
569
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lurasidone Hydrochloride
×
Clear all
NCT01431326
2023-09-06
PTN_POPS
Duke University
Completed
3,520 enrolled